Consolidated Balance Sheets - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Repayment of long-term debt	$ (6,348,646)
Current Assets
Cash and cash equivalents	25,426,166	$ 20,318,411
Accounts receivable, net of allowance for doubtful accounts of $0 at March 31, 2016 and December 31, 2015, respectively	2,612,832	2,566,101
Deferred costs	3,986,178	2,911,743
Prepaid expenses and other current assets	3,592,788	3,476,177
Total current assets	35,617,964	29,272,432
Property, plant and equipment, net	16,923,763	17,064,900
Goodwill	7,013,315	7,013,315
Intangible assets, net	2,735,380	2,877,880
Other assets	894,524	976,768
Total assets	63,184,946	57,205,295
Current Liabilities
Accounts payable	3,984,710	4,107,388
Accrued liabilities	6,322,955	6,198,488
Long-term debt, current	1,158,799	4,171,456
Notes payable, current	1,358,598	1,192,666
Unearned revenues	5,638,649	5,345,225
Total current liabilities	18,463,711	21,015,223
Long-term Liabilities
Deferred income taxes	986,040	932,662
Notes payable	450,427	583,041
Other Long-term Debt, Noncurrent	2,776,416	0
Long-term debt	7,492,555	10,828,544
Other long-term liabilities	432,802	562,001
Total liabilities	$ 30,601,951	$ 33,921,471
Commitments and Contingencies (see Note 15)
Redeemable Noncontrolling Interest, Equity, Carrying Amount	$ 19,400,000	$ 0
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2016 and December 31, 2015, respectively	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 59,123,260 and 56,733,012 shares, at March 31, 2016 and December 31, 2015, respectively	59,123	56,733
Additional paid-in capital	398,423,589	396,496,341
Treasury stock, at cost; 109,989 shares at March 31, 2016 and December 31, 2015, respectively	(707,637)	(707,637)
Accumulated deficit	(384,113,407)	(372,132,490)
Accumulated other comprehensive income	0	486
Total Caladrius Biosciences, Inc. stockholders' equity	13,661,768	23,713,533
Noncontrolling interests	(478,773)	(429,709)
Total equity	13,182,995	23,283,824
Liabilities and Equity, Total	$ 63,184,946	$ 57,205,295